JP2019502736A - 経表皮水分損失を予防又は低減するための組成物 - Google Patents
経表皮水分損失を予防又は低減するための組成物 Download PDFInfo
- Publication number
- JP2019502736A JP2019502736A JP2018538187A JP2018538187A JP2019502736A JP 2019502736 A JP2019502736 A JP 2019502736A JP 2018538187 A JP2018538187 A JP 2018538187A JP 2018538187 A JP2018538187 A JP 2018538187A JP 2019502736 A JP2019502736 A JP 2019502736A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- scfa
- tewl
- maternal
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 144
- 230000036572 transepidermal water loss Effects 0.000 title claims abstract description 101
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
- 230000008591 skin barrier function Effects 0.000 claims abstract description 33
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 11
- 230000008774 maternal effect Effects 0.000 claims description 43
- 235000016709 nutrition Nutrition 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 27
- 239000000835 fiber Substances 0.000 claims description 23
- 230000035935 pregnancy Effects 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 16
- 239000006041 probiotic Substances 0.000 claims description 16
- 235000018291 probiotics Nutrition 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 230000000529 probiotic effect Effects 0.000 claims description 14
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 12
- 230000004888 barrier function Effects 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 235000021243 milk fat Nutrition 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 2
- 235000012182 cereal bars Nutrition 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000037067 skin hydration Effects 0.000 claims 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 79
- 210000003491 skin Anatomy 0.000 description 35
- 201000004624 Dermatitis Diseases 0.000 description 27
- 208000010668 atopic eczema Diseases 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- -1 mono- Chemical class 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 208000017520 skin disease Diseases 0.000 description 9
- 229920001202 Inulin Polymers 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 229940029339 inulin Drugs 0.000 description 8
- 230000037365 barrier function of the epidermis Effects 0.000 description 7
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000016236 parenteral nutrition Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 210000001578 tight junction Anatomy 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000002895 organic esters Chemical class 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- 229920002488 Hemicellulose Polymers 0.000 description 3
- 229920000715 Mucilage Polymers 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 241001303601 Rosacea Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000157 polyfructose Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000021542 oral nutrition Nutrition 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009528 severe injury Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- YZWRNSARCRTXDS-UHFFFAOYSA-N tripropionin Chemical compound CCC(=O)OCC(OC(=O)CC)COC(=O)CC YZWRNSARCRTXDS-UHFFFAOYSA-N 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037884 Rash pruritic Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101150049485 SPINK5 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 101150046383 gene 5 gene Proteins 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1884—Short-chain fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Abstract
Description
皮膚の主要機能は、環境ストレスから身体を保護することと、脱水を防止することである。
本発明の目的は、経表皮水分損失及び/又はTEWL関連疾患の予防若しくは治療、並びに/又は乳児の皮膚バリア機能の増進という問題に対する、新規かつ代替的な解決策を提供することである。驚くべきことに、短鎖脂肪酸(SCFA)は、妊婦又は授乳婦に投与したとき、経表皮水分損失及び/又はTEWL関連疾患の予防若しくは治療において、及び/又は皮膚バリア機能の増進において、及び/又は授乳中の母親の子若しくは乳児の湿疹の予防に、有用であることが確認された。
用語「乳児」は、月齢18カ月未満の小児を指す。
1種以上のSCFAを組み込んだモノ−、ジ−及びトリ−アシルグリセロール誘導体等のグリセロール誘導体、例えばトリブチリン、トリアセチン、トリプロピオニン;
1つ以上のアシル鎖がSCFAからなるリン脂質誘導体、例えば、ホスファチジルコリン(phophatidylcholine)、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルエタノール(phospatidylethanol);
SCFAの有機エステル、例えば、メチル、エチル、プロピル又はイソプロピルエステル(そのようなSFCA有機エステルの非限定例は、エチルブタノエート、エチルプロピオネート、エチルアセテート等である);このようなエステルは、天然物でもよく、又は化学反応によって、例えば、SCFAと適切なアルコール(例えば、エチルアルコール)との縮合により、得られてもよい;
SCFAを組み込んだ繊維又はタンパク質、例えば、ブチレート化又はアセチル化された繊維、例えば、ブチレート化又はアセチル化されたデンプン;
発酵性繊維、例えば発酵性オリゴ糖及びデンプンである。発酵性繊維としては、限定するものではないが、ペクチン、粘漿剤、ガム、ガラクトオリゴ糖、オリゴフルクタン、イヌリン、ポリフルクトース、アラビノガラクトン、ヘミセルロース、オリゴ糖又はこれらの混合物が挙げられる。
項の見出しは主題を明確化するためのものであり、主題を限定するものと解釈すべきではない。値の範囲が開示されている場合、各個別の値、特に各整数は、その範囲に含まれるものとみなされる。別段の記載がない場合、%で表す値は、重量/重量(w/w)の値に関する。
本発明の組成物は、少なくとも1種の上記定義によるSCFA成分、又は1種のSCFA由来成分又はこれらの混合物を含む。
1種以上のSCFAを組み込んだモノ−、ジ−及びトリ−アシルグリセロール誘導体等のグリセロール誘導体、例えばトリブチリン、トリアセチン、トリプロピオニン;
1つ以上のアシル鎖がSCFAからなるリン脂質誘導体、例えば、ホスファチジルコリン(phophatidylcholine)、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルエタノール(phospatidylethanol);
SCFAの有機エステル、例えば、メチル、エチル、プロピル又はイソプロピルエステル(そのようなSFCA有機エステルの非限定例は、エチルブタノエート、エチルプロピオネート、エチルアセテート等である);このようなエステルは、天然物でもよく、又は化学反応によって、例えば、SCFAと適切なアルコール(例えば、エチルアルコール)との縮合により、得られてもよい;
SCFAを組み込んだ繊維又はタンパク質、例えば、ブチレート化又はアセチル化された繊維、例えば、ブチレート化又はアセチル化されたデンプン;
発酵性繊維、例えば発酵性オリゴ糖及びデンプンからなる群において選択される。発酵性繊維としては、限定するものではないが、ペクチン、粘漿剤、ガム、ガラクトオリゴ糖、オリゴフルクタン、イヌリン、ポリフルクトース、アラビノガラクトン、ヘミセルロース、オリゴ糖又はその混合物;
又はこれらの混合物が挙げられる。
上記の母体用組成物は、液体又は固形形態で配合することができる。組成物は、本開示を読めば当業者が特定することができる少なくとも1種の更なる活性作用物質、担体、ビヒクル、賦形剤、又は補助剤を更に含むことができる。
完全栄養組成物(すなわち、必須の主要栄養素及び微量栄養素を全て含有するもの)は、想定される被験体のための唯一の栄養供給源として使用することができる。患者は、その栄養所要量の100%をそのような完全栄養組成物から得ることができる。部分的又は不完全栄養組成物は、必須の主要栄養素及び微量栄養素の全て含有するわけではなく、想定される被験体のための唯一の栄養供給源として使用することができない。
1)タンパク質源;
2)オメガ3及び/又はオメガ6多価不飽和脂肪酸(DHA、DGLA、ETA、EPA、GLA、SDA)等の機能性脂肪酸、多価不飽和脂肪酸を含有する油又はこれらの組み合わせを含有及び/又は包含する脂質源;
3)炭水化物源;
4)ビタミン及びミネラル。組成物はまた、抗酸化物質、安定剤(固体形態で提供される場合)、又は乳化剤(液体形態で提供される場合)を含有してもよい。
上記の組成物はまた、キットとして提供されてもよい。こうしたキットにおいて、上記組成物の成分の全て又は一部は、別々の(すなわち混合されていない)形態で提供される。本発明のキットは、一方でSCFA成分、SCFA由来成分又はこれらの混合物を、他方で任意の他の成分を、別々の形態で含むことができる。本発明のキットは、別々の形態で提供される少なくとも2種又は3種のSCFA成分、SCFA由来成分又はこれらの混合物を含むことができる。代替の実施形態において、キットは、上記組成物の成分のそれぞれを別々の形態で含むことができる。
本発明の母体用組成物又はキットは、授乳中の母親の子及び/又は母乳栄養児における、経表皮水分損失の予防若しくは治療、及び/又はTEWL関連疾患の予防若しくは治療、及び/又は疾患に罹患していない被験体と比べて増大したTEWLによって特徴付けられる皮膚疾患の予防若しくは治療において、かつ/又は皮膚バリア機能を増進するために、使用することができる。
本発明の母体用組成物又はキットは、授乳中の母親の子及び/又は母乳栄養児における経表皮水分損失の予防若しくは治療、及び/又はTEWL関連疾患の予防若しくは治療、及び/又は該疾患に罹患していない被験体と比べて増大したTEWLによって特徴付けられる皮膚疾患の予防若しくは治療において、かつ/又は皮膚バリア機能を増進するために、非治療的に使用することができる。
上記の組成物の製造方法が提供され、該方法は、上記SCFA成分若しくはSCFA由来成分のうちの少なくとも1種又はそれらの混合物を用意することと、脂肪、タンパク質、炭水化物又は生理学的に許容される賦形剤からなる群から選択される少なくとも1種の更なる成分を任意選択的に添加することと、少なくとも1種の栄養素又は微量栄養素を任意選択的に添加することと、担体及び/又は水を添加することと、を含む。
雄のBalb/cマウス1匹と雌のBalb/cマウス2匹とを繁殖ペアとした。
妊娠1日目から、雌マウスに、200mMの酢酸ナトリウム又はプロピオン酸ナトリウムを飲料水で不断給餌した。投与量は、それぞれ0.05〜0.1及び0.05〜0.08g/マウス/日に相当する。対照雌マウスには、通常の飲料水を与えた。
同腹仔について、ケージを18〜24日目に観察した。仔が生まれるとすぐに、母親に通常の飲料水を再開した。実験中、1グループ当たり6〜7匹の仔が含まれた。
生後3日目にTEWLメーター法により経表皮水分損失を測定し、g・h−1・m−2単位で得た(ベースラインTEWL)。
雄のBalb/cマウス1匹と雌のBalb/cマウス2匹とを繁殖ペアとした。
妊娠1日目から、雌マウスに30%イヌリン強化した食餌を与えた。対照雌マウスには、非発酵性繊維のセルロースで30%強化した食餌を与えた。
同腹仔について、ケージを18〜24日目に観察した。仔が生まれるとすぐに、全ての母親に4%の混合繊維を含む通常の食餌を再開した。実験中、1グループ当たり5匹の仔が含まれた。
生後5日目にTEWLメーター法により経表皮水分損失を測定し、g・h−1・m−2単位で得た(ベースラインTEWL)。
Balb/cマウスに、離乳(生後21日)から4週間にわたり、30%の発酵性繊維イヌリンで強化した食餌又は30%のセルロースを含有する対照食を与えた。
離乳の4週間後に便を採取し、気液クロマトグラフィー(GLC;SCFAの量、μmol/g湿潤重量)によりSCFAの存在量を測定した。SCFAとして、アセテート、プロピオネート、ブチレート、バレレート、イソブチレート、及びイソバレレートを測定した。結果を図3に示す。
測定は、次のプロトコルに基づいて実施した:酸性溶液(pH2.0〜20 3.0)中のSCFAを、極性固定相で被覆されたGLCカラムで分離した。これにより、試料の調製が最小限でよく(誘導体化なし)、塩基性FID検出が直接できる。SCFAは、HgCl2を含有する酸性リン酸緩衝剤を用いて、便から抽出した。
Claims (16)
- 少なくともSFCA成分若しくは少なくともSCFA由来成分又はこれらの混合物を含む母体用組成物であって、前記母体用組成物が投与された女性の、子又は母乳栄養児において、経表皮水分損失(TEWL)及び/又はTEWL関連疾患の予防及び/若しくは治療に使用するための、かつ/又は皮膚バリア機能の増進に使用するための、母体用組成物。
- 前記母体用組成物が投与された女性の、子又は母乳栄養児において、経表皮水分損失(TEWL)及び/又はTEWL関連疾患の治療的予防及び/若しくは治療に使用するための、かつ/又は皮膚バリア機能の増進に使用するための、請求項1に記載の母体用組成物。
- アトピー性皮膚炎、乾燥肌若しくは反応性皮膚、又は皮膚の脱水等のTEWL関連疾患の予防又は治療に使用するための、請求項1又は2に記載の母体用組成物。
- 前記SCFA成分及び/又はSCFA由来成分が、アセテート、プロピオネート、ブチレート、発酵性繊維若しくはオリゴ糖、又はこれらの混合物から選択される、請求項1〜3のいずれか一項に記載の母体用組成物。
- 前記SCFA成分及び/又はSCFA由来成分が、アセテート、プロピオネート、又はこれらの混合物から選択される、請求項1〜4のいずれか一項に記載の母体用組成物。
- 妊娠中及び/又は授乳中に母体投与するための、請求項1〜5のいずれか一項に記載の母体用組成物。
- 前記子における経表皮水分損及び/又はTEWL関連疾患の予防のために、及び/又は皮膚バリア機能の増進のために、妊娠中に母体投与するための請求項1〜6のいずれか一項に記載の母体用組成物。
- 前記SCFA成分又はSCFA由来成分が、酢、又はバター等の乳脂肪由来食品である、請求項1〜7のいずれか一項に記載の母体用組成物。
- 前記組成物が、経口投与される、請求項1〜8のいずれか一項に記載の母体用組成物。
- 前記組成物が、多価不飽和脂肪酸を含む、請求項1〜9のいずれか一項に記載の母体用組成物。
- 前記組成物が、プロバイオティクスを含む、請求項1〜10のいずれか一項に記載の母体用組成物。
- 前記組成物が、多価不飽和脂肪酸及びプロバイオティクスを含む、請求項1〜11のいずれか一項に記載の母体用組成物。
- 前記組成物が、栄養組成物、経口栄養補給剤又は医薬品である、請求項1〜12のいずれか一項に記載の母体用組成物。
- 前記栄養組成物が、飲料製品、ヨーグルト製品、発酵乳、果汁、又はシリアルバーからなる群から選択される、請求項13に記載の母体用組成物。
- 少なくともSCFA成分若しくは少なくともSCFA由来成分又はこれらの混合物を含む母体用組成物の使用であって、前記母体用組成物が投与された妊婦又は授乳婦の子又は母乳栄養児において、経表皮水分損失(TEWL)及び/TEWL関連疾患を予防及び/若しくは治療するための、かつ/又は皮膚バリア機能を増進するための、使用。
- かかる使用が非治療的である、請求項15に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16152740.3 | 2016-01-26 | ||
EP16152740 | 2016-01-26 | ||
PCT/EP2017/051583 WO2017129643A1 (en) | 2016-01-26 | 2017-01-26 | Composition for preventing or reducing transepidermal water loss |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019502736A true JP2019502736A (ja) | 2019-01-31 |
JP6993340B2 JP6993340B2 (ja) | 2022-02-03 |
Family
ID=55237544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018538187A Active JP6993340B2 (ja) | 2016-01-26 | 2017-01-26 | 経表皮水分損失を予防又は低減するための組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10751308B2 (ja) |
EP (1) | EP3407878A1 (ja) |
JP (1) | JP6993340B2 (ja) |
CN (1) | CN108472274A (ja) |
WO (1) | WO2017129643A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3897835A1 (en) * | 2018-12-19 | 2021-10-27 | Société des Produits Nestlé S.A. | Composition for preventing or reducing transepidermal water loss and improving skin barrier function |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006115412A2 (en) * | 2005-04-27 | 2006-11-02 | N.V. Nutricia | Nutrition with lipids and non-digestible saccharides |
JP2007538067A (ja) * | 2004-05-17 | 2007-12-27 | エヌ.ブイ.・ヌートリシア | Gosとポリフルクトースとの相乗作用 |
WO2012069415A1 (en) * | 2010-11-23 | 2012-05-31 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662954A (en) * | 1994-07-05 | 1997-09-02 | Joiner; Margie | Method for preparing mineral-enriched citrate compositions |
JP2000319171A (ja) * | 1999-03-03 | 2000-11-21 | Nof Corp | 殺菌性皮膚外用剤組成物 |
RU2462252C2 (ru) * | 2006-03-10 | 2012-09-27 | Н.В. Нютрисиа | Применение неусвояемых сахаридов для лучшей адаптации младенцев после рождения |
EP2348890B1 (en) * | 2008-03-28 | 2013-09-18 | Nestec S.A. | Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings |
US8137718B2 (en) * | 2008-09-19 | 2012-03-20 | Mead Johnson Nutrition Company | Probiotic infant products |
CN104546880B (zh) * | 2015-01-07 | 2017-12-12 | 中国医科大学附属第一医院 | 一种治疗面部脂溢性皮炎的外用制剂 |
-
2017
- 2017-01-26 EP EP17702335.5A patent/EP3407878A1/en active Pending
- 2017-01-26 US US16/071,530 patent/US10751308B2/en active Active
- 2017-01-26 CN CN201780005466.2A patent/CN108472274A/zh active Pending
- 2017-01-26 WO PCT/EP2017/051583 patent/WO2017129643A1/en active Application Filing
- 2017-01-26 JP JP2018538187A patent/JP6993340B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007538067A (ja) * | 2004-05-17 | 2007-12-27 | エヌ.ブイ.・ヌートリシア | Gosとポリフルクトースとの相乗作用 |
WO2006115412A2 (en) * | 2005-04-27 | 2006-11-02 | N.V. Nutricia | Nutrition with lipids and non-digestible saccharides |
WO2012069415A1 (en) * | 2010-11-23 | 2012-05-31 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
Non-Patent Citations (2)
Title |
---|
INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, vol. 66, no. 7, JPN6020050007, 2015, pages 755 - 765, ISSN: 0004639665 * |
THE LANCET, vol. 357, JPN6020050005, 2001, pages 1076 - 1079, ISSN: 0004639664 * |
Also Published As
Publication number | Publication date |
---|---|
CN108472274A (zh) | 2018-08-31 |
EP3407878A1 (en) | 2018-12-05 |
US10751308B2 (en) | 2020-08-25 |
WO2017129643A1 (en) | 2017-08-03 |
JP6993340B2 (ja) | 2022-02-03 |
US20190029981A1 (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3478306B1 (en) | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal | |
EP3177151B1 (en) | Vitamin b2 and myo-inositol for treating and preventing gestational diabetes | |
EP3177155B1 (en) | Myo-inositol and one or more probiotic and use thereof | |
EP3265099B1 (en) | Human milk oligosaccharides for treating acute respiratory tract infections | |
US20080254012A1 (en) | Nutritional Formulation For Promoting Catch-Up Growth | |
CN103582426A (zh) | 寡糖混合物以及包含该混合物的食品,特别是婴儿配方产品 | |
EP3177277B1 (en) | Myo-inositol and probiotics and uses | |
US20160316808A1 (en) | Synthetic nutritional compositions especially adapted for male and female infants and young children | |
US11141442B2 (en) | Tributyrin compositions and methods therefor | |
JP2016505024A5 (ja) | ||
JP2016505024A (ja) | 生存可能なプロピオン酸を生成する細菌を含有するベビーフード組成物 | |
EP3177154B1 (en) | Myo-inositol and probiotics, and their use to prevent excess body weight in infants | |
KR20220107011A (ko) | 임산부의 미생물총을 개선하기 위한 hmo의 혼합물 | |
JP6993340B2 (ja) | 経表皮水分損失を予防又は低減するための組成物 | |
CA2994352A1 (en) | Methods and compositions using bifidobacterium longum to optimize breastfeeding | |
CN112806577B (zh) | 产丁酸的益生元益生菌增效组合 | |
BR112021004949A2 (pt) | composições nutricionais, seu uso na redução do estresse metabólico e método para reduzir o estresse metabólico | |
BR112017001807B1 (pt) | Composição e combinação para administração materna compreendedo mioinositol e um ou mais probióticos, seu uso, e kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210412 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211008 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211008 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211020 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6993340 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |